Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis
Authors:
- 3 May 2007
- journal article
- Published by Springer Nature in Leukemia
- Vol. 21 (8) , 1824-1826
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disordersBlood, 2006
- Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disordersBlood, 2006
- The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disordersBlood, 2005
- Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersBlood, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- Granulocyte–Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CMLNew England Journal of Medicine, 2004
- Involvement of Jak2 tyrosine phosphorylation in Bcr–Abl transformationOncogene, 2001
- The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid MetaplasiaBritish Journal of Haematology, 1999